Tryptophan transport

Across TCGA cell cohorts, RNA activity of the Tryptophan transport pathway is significantly associated with the drug response of multiple features, with the CNS cohort showing a particularly strong set of associations.

The most reproducible pathway-associated features across cancer lineages are LIMK1 inhibitor BMS4, Daporinad, and Bexarotene, each associated with the pathway in up to 2 cancer types. Since the analysis shows associations rather than directional relationships, both pathway-to-partner and partner-to-pathway views are reported.

Each partner is linked to its corresponding Q-omics profile. The box plot shows the strongest association, LIMK1 inhibitor BMS4 grouped by Tryptophan transport-low versus -high activity in CNS.

Pathway-associated features by consensus

Ranked by combined sampling and lineage consensus. X-score (pathway→partner) and Y-score (partner→pathway) are standardized regression coefficients; both directions are reported because the association is undirected. The reported p-values are derived from the association test.

Lineage	Partner feature	X-score	Y-score	p(X)	p(Y)	Sampling consensus	Lineage consensus
CNS	LIMK1 inhibitor BMS4 →	-0.490	-0.604	.031	.028	1	2
CNS	Daporinad →	+0.605	+0.604	.026	.028	1	1
CNS	Bexarotene →	+0.424	+0.604	.016	.028	1	1
CNS	Zibotentan →	+0.084	+0.604	.042	.028	1	1
CNS	Amuvatinib →	+0.764	+0.604	.048	.028	1	1
CNS	Voxtalisib →	-0.239	-0.604	.004	.028	1	1

Each partner links to its Q-omics profile. Showing the 6 strongest associations by consensus.

LIMK1 inhibitor BMS4 by Tryptophan transport activity — CNS

Explore this box plot interactively →